QuidelOrtho Science BYTES Podcast

Our latest episode of QuidelOrtho Science Bytes addresses a public health paradox: while early-stage syphilis cases in the U.S. are declining, congenital syphilis continues to rise despite being entirely preventable. Host Josh Casey is joined by Andrea Ott‑Vasconi, Director of Scientific Affairs and Regulatory at QuidelOrtho, to unpack CDC data and explain why missed or delayed screening during pregnancy is driving congenital infections. Together, they explore how syphilis testing works, when infections are being missed and why repeat screening is essential, especially later in pregnancy. About Our Speaker: Andrea Ott-Vasconi, Director of Scientific Affairs and Regulatory at QuidelOrtho Andrea holds a Bachelor of Science in Biomedical Engineering from Johns Hopkins University and an MBA from New York University. Most recently, she earned a Master of Public Health from Imperial College London. With over 20 years of experience in the medical device industry, Andrea has worked in many different roles, including product development and clinical marketing. In her current role at QuidelOrtho, she manages a team responsible for the development of educational content, scientific publications and evidence generation. Andrea is passionate about increasing awareness of the clinical value of laboratory tests and their impact on improving patient outcomes.

Our 55th episode of QuidelOrtho Science Bytes features Michelle Mullens, Global Portfolio Marketing Manager for Transfusion Medicine, diving into the evolving realities of today’s blood supply, and why steady, year‑round donation is critical to modern healthcare. From the constant demand driven by everyday trauma to climate‑related disruptions that strain regional inventories, shifting prehospital practices that rely heavily on universal blood types and the growing role of automation in stabilizing testing workflows, this episode explores the interconnected systems that keep patients safe. Mullens shares how donor habits, resilient infrastructure and smarter immunohematology platforms help ensure blood is available when and where it’s needed most. Sustaining the blood supply isn’t just about meeting demand, it’s about building a resilient, connected system where donors, diagnostics and clinical care work together to protect patients every day. About Our Speaker: Michelle Mullens Global Portfolio Marketing Manager for Transfusion Medicine, QuidelOrtho Michelle brings invaluable insight to both the science and human impact of blood donation. Before starting her career on the corporate side, Michelle was a Senior Medical Technologist at Baptist Health, serving in leadership roles for transfusion medicine and immunohematology. Prior to taking on her current role in the global business unit at QuidelOrtho, Michelle served as a technical specialist, business development consultant and clinical science liaison. With significant experience in the blood bank and as a trusted provider to the profession, Michelle brings a unique perspective to the conversation today.

Our 53rd episode of QuidelOrtho Science Bytes features Dr. Qian Ding, MD, PhD, exploring why early detection of diabetes is a clinical and economic imperative. From identifying silent disease progression to leveraging smarter lab platforms, early testing empowers clinicians to intervene sooner, personalize care and help prevent costly complications. Dr. Ding shares how diagnostics and emerging biomarkers are helping reshape diabetes care – delivering fast, reliable insights that support proactive treatment and healthier outcomes. About Our Speaker: Dr. Qian Ding, MD, PhD Dr. Ding brings extensive experience in hospital laboratory and in vitro diagnostics with a strong command of healthcare information systems and data analytics. With a comprehensive background in microbiology, immunology, molecular genetics and healthcare business intelligence, Dr. Ding is also an accomplished researcher with an established record of publications in reputable peer-reviewed scientific journals. She's also recognized as a leader at the intersection of science, technology and healthcare.

This episode features Dr. Terry O’Neil, President and Medical Director of Urgent Care Pros, discussing why testing is essential when symptoms overlap during respiratory season. With conditions like strep, flu, RSV and COVID-19 often appearing similar at the outset, timely diagnostics provide clarity for both treatment and prevention.Dr. O’Neil shares how rapid testing empowers urgent care providers to give patients clear answers, start appropriate treatment quickly, and reduce the risk of spreading illness to vulnerable family members and communities. About Our Speaker: Dr. O’Neil is a board-certified ER doctor and the president and medical director of Urgent Care Pros, a group of walk-in clinics providing fast and easy access to quality care. He has over 20 years of emergency room experience and a deep commitment to caring for patients. A graduate of Columbia University, Dr. O’Neil recognized the need for fast, efficient and specialized care in both urgent care and occupational health settings, which led him to establish Urgent Care Pros in January 2020. His approach reflects the mission of Urgent Care Pros, that is to provide unparalleled customer service and specialized health support in an affordable manner, ensuring patients receive the care they need when they need it most. Beyond his clinical work, Dr. O’Neil enjoys traveling, skiing and staying active through fitness, bringing the same energy and commitment to his personal life as he does to caring for his patients.

In this episode, you'll hear a conversation with our own Vonda McAllister about the critical role of rapid diagnostic testing in helping prevent drug overdose deaths. Discover how early detection in emergency departments enables timely interventions when patients present with altered mental status or respiratory distress. The discussion explores the evolving landscape of substance abuse in 2025, including synthetic opioids like fentanyl, emerging threats like xylazine ("tranq") and the challenges of polydrug use, creating unpredictable and potentially fatal combinations. About Our Speaker: Vonda McAllister, Director of Global Product Management. Vonda's diagnostic experience spans from R&D and program management to marketing. Now a member of the Point of Care business unit, she previously managed the Triage™ portfolio of assays and the clinical labs team for North America. Vonda is currently focused on supporting the global regions with our PlGF tests, that is, placental growth factor, and toxicology assays, as well as expanding the Triage toxicology and women's health testing portfolio. She also serves as global leadership co-chair for the QuidelOrtho Women's Leadership Network.

In this episode, you'll hear a conversation with three women's health experts about how early diagnostic testing is transforming care for heart disease, STIs, and preeclampsia. Discover how proactive screening empowers women, supports personalized care, and helps shift healthcare from reaction to prevention. About Our Speakers: Dr. Lindy Crimmins, Global Medical Affairs Manager. Lindy's clinical experience spans from emergency medicine to critical and primary care. Currently, she is responsible for providing medical support for the QuidelOrtho acute care menu throughout the product lifecycle. Lindy is passionate about education, testing guideline updates and assay utilization to drive improved patient-centered outcomes. Dr. Rea Castro, Director of Medical Affairs. Rea is a seasoned medical professional with extensive experience in pharmaceutical clinical development, biotechnology and diagnostic product development across multiple therapeutic areas, including immunology, oncology and women's health. She is currently a cross-functional leader in medical affairs and is committed to advancing healthcare outcomes through innovative research, quality healthcare delivery and rigorous safety standards. Vonda McAllister, Director of Global Product Management. Vonda's diagnostic experience spans from R&D and program management to marketing. Now a member of the Point of Care business unit, she previously managed the Triage™ portfolio of assays and the clinical labs team for North America. Vonda is currently focused on supporting the global regions with our PlGF tests, that is, placental growth factor, and toxicology assays, as well as expanding the Triage toxicology and women's health testing portfolio. She also serves as global leadership co-chair for the QuidelOrtho Women's Leadership Network.

This episode discusses the growing threat of sepsis, a life-threatening condition caused by the body's overwhelming response to an infection. It explores the connection between the rise in sepsis cases and the increasing problem of antibiotic resistance, highlighting the importance of effective diagnostic tools and antibiotic stewardship programs in combating this public health challenge. About Our Speaker: Dr. Mike Broyles With more than 30 years of experience as a hospital pharmacy and laboratory director, Dr. Broyles is a leading expert on sepsis and the clinical use of drugs with a focus on antimicrobial stewardship. Prior to joining Thermo Fisher Scientific, Dr. Broyles was a consultant for over 25 years working with a large independent hospital network as pharmacy advisor chairman focused on developing and implementing hospital-wide clinical initiatives. Dr. Broyles has worked passionately throughout his career to define effective protocols and decision support processes in patient management and the use of diagnostic technology to help clinicians improve outcomes through better clinical care.

In this episode, we’ll explore how quality performance metrics are transforming clinical laboratory operations and why measuring the details – from accuracy to turnaround times – are essential for improving everything from test results to patient care. About Our Speaker: Johanna Miller, Global Product Manager for QuidelOrtho. Johanna brings a wealth of expertise working with laboratory metrics. She also has a strong background in data science, and she recently published a peer-reviewed article on a novel approach to leveraging big data to calculate Sigma metrics using input from real-world clinical laboratories. Johanna has also worked closely with lab teams to build the discipline to provide metrics they can use to improve their performance. She's passionate about helping lab staff achieve excellence through data and innovation, and today she'll share her insights on how metrics can help teams navigate challenges, prioritize improvements and ultimately deliver the best possible patient outcomes.

The syphilis epidemic in the U.S. is a growing public health crisis, with rates increasing by 76% from 2018 to 2022. Syphilis is preventable and curable, but early detection is key—especially for pregnant women, where timely testing can prevent congenital syphilis. Don’t miss this episode on the solutions to this growing epidemic. About Our Speaker: Dr. Lily Li is the Senior Director of Medical, Scientific & Clinical Affairs at QuidelOrtho. With a medical degree from Peking University and a PhD in Immunology from the University of Alberta, Dr. Li has guided the development of multiple infectious disease diagnostic tests at QuidelOrtho.

The World Health Organization estimates 3.7 billion people under age 50 (67%) globally have herpes simplex virus type 1 (HSV-1) infection, the main cause of oral herpes, and 491 million people aged 15–49 (13%) worldwide have a herpes simplex virus type 2 (HSV-2) infection, the main cause of genital herpes. Although treatable, most HSV infections are often asymptomatic or unrecognized. Moreover, management of HSV infections is complicated by overlapping clinical presentation of unrelated herpesvirus infections, such as varicella-zoster virus (VZV), requiring differential diagnosis. Innovations in molecular diagnostics continue to play a critical role in the diagnosis and management of these diseases. About Our Speaker: Lori Henderson earned a bachelor’s degree in biology from Bucknell University. She began her career in the laboratory working on drug discovery and then transitioned into commercial roles within the biopharma and diagnostics sectors of the life science industry. Lori has direct experience in multiple disease and therapeutic areas and currently focuses on sexually transmitted diseases and women’s health. Within the molecular business unit at QuidelOrtho, Lori is responsible for identifying and helping drive the development of products to meet clinical and patient needs.

Six Sigma is a popular way to measure quality. Sigma metrics have been adapted for the clinical laboratory by incorporating observed accuracy, precision and total error allowed (TEa). In vitro diagnostic (IVD) manufacturers have used Six Sigma to assess the quality of their assays using a small number of well-controlled systems to generate the data. QuidelOrtho has developed a novel approach to assess laboratory Sigma metrics for a broad range of assays using data from over 1,300 Vitros® instruments used in clinical labs. In this podcast, Johanna Miller, data scientist at QuidelOrtho, discusses the value of using real-world data to perform Sigma metric studies and how a lab can use this information. About Our Speaker: Johanna Miller holds a bachelor's degree in biomedical engineering from the University of Rochester and a master's in product development and data science from the Rochester Institute of Technology. She spent 10 years developing expertise on Vitros systems and the data it generates, while working in product development. Currently, she focuses on developing new and interesting methods to use data at QuidelOrtho - specifically to bring insights directly to labs using Six Sigma quality scores.

Each year 4.5 million lives are saved by blood transfusions thanks to blood donations. More than 118 million units of blood are donated worldwide every year but less than 10% of people who can donate blood will give. These repeat blood donors enjoy benefits of their own while providing their lifesaving gift. Donating blood burns 650 calories, reduces stress, provides an emotional lift and has physiological benefits. In this podcast, Dr. Mark A. Levine shares the critical importance of blood donation and how repeat donors enjoy both emotional and physical health benefits. About Our Speaker: Dr. Levine is an award-winning physician and lecturer with interests in health professional education, the history of medicine and community empowerment. For 14 years, he served as Chief Medical Officer at the Centers for Medicare and Medicaid Services in Denver. Dr. Levine founded the Colorado Patient Safety Coalition and served as chair of the American Medical Association’s Council on Ethical & Judicial Affairs. He received his bachelor’s degree from Rutgers University and medical degree from Temple University School of Medicine. Dr. Levine’s father, Dr. Phillip Levine, was a pioneering hematologist who joined Ortho Products in 1944 and his breakthrough discovery of Rh factor led to advancements in hemolytic disease of the newborn and safe blood transfusions saving countless lives.

Alloimmune hemolytic disease of the fetus and newborn (HDFN) may occur when a pregnant woman has an antibody against an antigen on the fetal red cells inherited from the father. Many antibodies to red blood cell antigens can cause HDFN, including those from the ABO, Rh, and other blood group systems. Women can develop antibodies either through previous pregnancy or transfusion. Fatal consequences from this disorder have become rare with the appropriate use of immunoprophylaxis. However, to avoid the fatal consequences of this disorder, prompt recognition and treatment are vital. The risk for HDFN can be identified by testing the mother with an ABO group/Rh and antibody screen during the pregnancy. RhD HDFN can be prevented through passive anti-D administration to suppress the mother’s immune response against the fetal RhD antigen. Some women may exhibit weak or discrepant results on RhD typing, or current results may differ from historical results. A common type of RhD variant is the weak D phenotype. Women with this phenotype have a weak expression of the RhD antigen and may present with variable RhD typing depending on the antisera or testing method used in the laboratory. Another type of RhD variant is the partial D phenotype where the RhD antigen is altered, potentially allowing an individual to form alloantibodies to the epitopes on RhD-positive red blood cells that are different than their own. In this podcast episode, we will discuss the types of HDFN, the role that partial D groups, and the presence of anti-D as it relates to its prevalence, prognosis, and management. About our Speaker: Dr. Genghis Lopez is a Senior Scientist at the Australian Red Cross Lifeblood in Brisbane, Australia. Genghis received his Ph.D. degree from Griffith University, Australia. At Lifeblood, he worked at the Platelet and Granulocyte Reference Laboratory and Red Cell Reference Laboratory and is now part of the Transfusion Science research team that investigates complex red cell blood group variants. He has published several papers in Vox Sanguinis and Transfusion journals reporting novel red cell antigens, novel blood types, and red cell antibodies including several associated with hemolytic transfusion reactions or hemolytic disease of the fetus and the newborn.